Xenetic Biosciences Inc(XBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XBIO Xenetic Biosciences Inc

Post-Mkt 12-08 17:06:28 EST

2.44

-0.09

-3.56%

盘后2.47

+0.03+1.23%

17:06 EST

High2.53	Low2.37	Vol27.27K
Open2.53	D1 Closing2.53	Amplitude6.32%
Mkt Cap5.59M	Tradable Cap4.68M	Total Shares2.29M
T/O67.28K	T/O Rate1.42%	Tradable Shares1.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XBIO","market":"US","secType":"STK","nameCN":"Xenetic Biosciences Inc","latestPrice":2.44,"timestamp":1765227600000,"preClose":2.53,"halted":0,"volume":27272,"hourTrading":{"tag":"盘后","latestPrice":2.47,"preClose":2.44,"latestTime":"17:06 EST","volume":1004,"amount":2476.7600700000003,"timestamp":1765231567928},"delay":0,"floatShares":1917800,"shares":2291056,"eps":-2.046703,"marketStatus":"Post-Mkt","change":-0.09,"latestTime":"12-08 17:06:28 EST","open":2.53,"high":2.53,"low":2.37,"amount":67276.87681120001,"amplitude":0.063241,"askPrice":2.55,"askSize":2,"bidPrice":2.4,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.046703,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765242000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.53,"preHourTrading":{"tag":"盘前","latestPrice":2.5644,"preClose":2.53,"latestTime":"08:40 EST","volume":630,"amount":1607.9000489999999,"timestamp":1765201203130},"postHourTrading":{"tag":"盘后","latestPrice":2.47,"preClose":2.44,"latestTime":"17:06 EST","volume":1004,"amount":2476.7600700000003,"timestamp":1765231567928},"volumeRatio":0.908413,"impliedVol":2.5089,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/XBIO","defaultTab":"news","newsList":[{"id":"2584976944","title":"Xenetic Biosciences Extends Research Collaboration with Scripps Research to Advance DNase Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2584976944","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584976944?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:45","pubTimestamp":1763559918,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Inc. has extended its research and development collaboration with The Scripps Research Institute and Dr. Alexey Stepanov's laboratory. The partnership will continue for an additional four months starting November 1, 2025, focusing on advancing Xenetic's DNase I platform in combination with CAR T-cell therapies. The collaboration aims to further evaluate the therapeutic potential of systemic DNase I, particularly in improving responses to CAR-T cell therapy for both hematologic and solid tumors. Preclinical studies have shown promising results, and the program is being advanced toward Phase 1 clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL18nwzM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2583593734","title":"Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593734","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593734?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:46","pubTimestamp":1763041561,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL8mrjgp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"gpt_icon":0},{"id":"2583932535","title":"Xenetic Biosciences Q3 Net Income USD -500 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2583932535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583932535?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:45","pubTimestamp":1763041546,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXE08C41:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2575218066","title":"Xenetic Biosciences Announces $4.5 Million Underwritten Offering of Common Stock at $6.12 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2575218066","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575218066?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:49","pubTimestamp":1760446174,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences, Inc.  has announced the pricing of an underwritten offering of 735,000 shares of common stock at $6.12 per share, expecting to raise approximately $4.5 million in gross proceeds before expenses. All shares are being offered by Xenetic, with Canaccord Genuity LLC serving as the sole bookrunner for the transaction. The company plans to use the net proceeds for working capital and other general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely respons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLc6PnR6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2574100439","title":"Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges","url":"https://stock-news.laohu8.com/highlight/detail?id=2574100439","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574100439?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:44","pubTimestamp":1760129040,"startTime":"0","endTime":"0","summary":"Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companies that stood out this week.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/10/Binary-Options-Chart_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/10/Binary-Options-Chart_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/25/10/48161813/micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/10/48161813/micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4532","LU0127658192.USD","LU2286300806.USD","USJW.SI","LU2211815571.USD","LU2931357623.SGD","NQmain","LU0081259029.USD","TSYW.SI","SQQQ","GLTO","USAW.SI","BK4585","LU1316542783.SGD","QLD","BK4527","IE0002270589.USD","XBIO","BK4543","BK4139","LU0082616367.USD","MNQmain","LU2360106780.USD","MU","QID","BK4512","BK4533","LU2089985449.USD","BK4588","LU0157215616.USD","IE00B19Z3581.USD","LU0792757196.USD","NVIW.SI","BK4141","LU0056508442.USD","BK4605","TQQQ","IE00B7SZLL34.SGD","LU2250418816.HKD","LU1852331112.SGD","LU0274383776.USD","LU0889566641.SGD","PSQ","BK4553","BK4575","LU0719512351.SGD","BK4566",".IXIC","GB00BDT5M118.USD"],"gpt_icon":1},{"id":"2574170025","title":"Xenetic Biosciences trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2574170025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574170025?lang=en_us&edition=fundamental","pubTime":"2025-10-10 23:20","pubTimestamp":1760109648,"startTime":"0","endTime":"0","summary":"11:16 EDT Xenetic (XBIO) Biosciences trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenetic-biosciences-trading-resumes-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenetic-biosciences-trading-resumes-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBIOW","XBIO"],"gpt_icon":0},{"id":"2574017430","title":"Xenetic 735,000 share Spot Secondary priced at $6.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2574017430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574017430?lang=en_us&edition=fundamental","pubTime":"2025-10-10 21:40","pubTimestamp":1760103648,"startTime":"0","endTime":"0","summary":"Xenetic (XBIO) Biosciences announced the pricing of an underwritten offering of 735,000 shares of common stock at a price to the public of $6.12 pe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenetic-735000-share-spot-secondary-priced-at-6-12-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenetic-735000-share-spot-secondary-priced-at-6-12-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2574171448","title":"Xenetic Biosciences Announces 45 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2574171448","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574171448?lang=en_us&edition=fundamental","pubTime":"2025-10-10 21:30","pubTimestamp":1760103058,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Inc. has announced the pricing of an underwritten offering of 735,000 shares of common stock at $6.12 per share, totaling approximately $4.5 million in gross proceeds before deductions. All shares are being offered by Xenetic, with Canaccord Genuity acting as the sole bookrunner for the offering. The company plans to use the net proceeds for working capital and other general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL9GzKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2574171413","title":"Xenetic Biosciences Inc Files for Offering to Sell Shares of Common Stock- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2574171413","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574171413?lang=en_us&edition=fundamental","pubTime":"2025-10-10 21:30","pubTimestamp":1760103053,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR1PX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2574161136","title":"4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings","url":"https://stock-news.laohu8.com/highlight/detail?id=2574161136","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574161136?lang=en_us&edition=fundamental","pubTime":"2025-10-09 23:12","pubTimestamp":1760022720,"startTime":"0","endTime":"0","summary":"Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs. Here's a look at four stocks flashing strong momentum signals.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/09/Democrats-Slam-Government-Shutdown-And-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/09/Democrats-Slam-Government-Shutdown-And-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/25/10/48128062/4-stocks-in-the-same-sector-just-made-a-huge-leap-in-momentum-rankings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/10/48128062/4-stocks-in-the-same-sector-just-made-a-huge-leap-in-momentum-rankings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","NQmain","TCRT","NVIW.SI","UPC","USJW.SI","QID","XBIO","SQQQ","BK4007","TQQQ","MNQmain","USAW.SI","QLD","PSQ",".IXIC","GLTO","TSYW.SI"],"gpt_icon":1},{"id":"2573693924","title":"Nasdaq Gains 150 Points; US Mortgage Applications Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2573693924","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573693924?lang=en_us&edition=fundamental","pubTime":"2025-10-08 22:22","pubTimestamp":1759933355,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/10/48101541/nasdaq-gains-150-points-us-mortgage-applications-decline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YYAI","USAW.SI","QLD","COCH",".IXIC","BK4082","USJW.SI","BK4190","TQQQ","SQQQ","ZNB","BK4204","MNQmain","NQmain","BK4122","BK4139","PCOM","TSYW.SI","QID","XBIO","NVIW.SI","PSQ","ATON"],"gpt_icon":1},{"id":"2573928451","title":"Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928451?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:01","pubTimestamp":1759924882,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks are soaring on Wednesday in what appears to be a continuation of yesterday’s speculative trading for Galecto.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-are-pharmaceutical-stocks-xbio-upc-xtlb-acxp-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-are-pharmaceutical-stocks-xbio-upc-xtlb-acxp-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","XBIO","XTLB","BK4563","BK4007","ACXP","UPC"],"gpt_icon":0},{"id":"2573194078","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2573194078","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573194078?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:40","pubTimestamp":1759923611,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences (XBIO) shares were up more than three-fold, or 196%, pre-bell Wednesday, adding to Tuesday's gains.AlphaTON Capital (ATON) stock was up 196% after the company said it entered into ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UPC","ATON","ACXP","XBIO","BK4539","BK4007","BK4139","BK4563"],"gpt_icon":0},{"id":"2559604802","title":"Xenetic Biosciences Q2 Net Income USD -700 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2559604802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559604802?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:00","pubTimestamp":1755086402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nPLX0C8596:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2559622147","title":"Xenetic Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559622147","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559622147?lang=en_us&edition=fundamental","pubTime":"2025-08-13 05:54","pubTimestamp":1755035640,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Inc reports results for the quarter ended June 30 - Earnings SummaryXenetic Biosciences Inc XBIO.OQ reported a quarterly adjusted loss of 45 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U42BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO"],"gpt_icon":0},{"id":"2558728065","title":"Xenetic Biosciences Inc  expected to post a loss of 64 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558728065","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558728065?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:23","pubTimestamp":1754684600,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Inc  expected to post a loss of64cents a share - Earnings Preview Xenetic Biosciences Inc XBIO.OQ XBIO.O is expected to  show a fall in quarterly revenue when it reports  results o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U03FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO"],"gpt_icon":0},{"id":"2555104421","title":"Xenetic Biosciences Announces New Clinical Study Agreement with PeriNess to Advance DNase Platform for Large B Cell Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2555104421","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555104421?lang=en_us&edition=fundamental","pubTime":"2025-07-30 21:00","pubTimestamp":1753880452,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Announces New Clinical Study Agreement with PeriNess to Advance DNase Platform for Large B Cell Lymphoma Treatment. Xenetic Biosciences, Inc. has announced a new clinical study agreement with its collaboration partner, PeriNess Ltd., to explore the potential of DNase I in combination with anti-CD19 CAR T cells for treating large B cell lymphoma. This investigator-initiated study, to be conducted at the Tel-Aviv Sourasky Medical Center, will primarily assess the safety and tolerability of this combination therapy. Secondary objectives include evaluating the efficacy through complete response rate, duration of response, and overall survival. The study aims to improve clinical outcomes by addressing the negative effects of Neutrophil Extracellular Traps  on CAR T-cell performance. Results of the study have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL3bgY2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBIO","BK4139"],"gpt_icon":0},{"id":"2553485012","title":"Xenetic Biosciences Expands Research Collaboration with Scripps Research to Advance DNase Platform for Lymphoma and Leukemia Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2553485012","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553485012?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:30","pubTimestamp":1753273825,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences Expands Research Collaboration with Scripps Research to Advance DNase Platform for Lymphoma and Leukemia Models. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL10gY8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"gpt_icon":0},{"id":"2549547479","title":"Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2549547479","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549547479?lang=en_us&edition=fundamental","pubTime":"2025-07-08 21:00","pubTimestamp":1751979633,"startTime":"0","endTime":"0","summary":"Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps  in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL69MZ4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XBIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xeneticbio.com","stockEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0866},{"period":"3month","weight":-0.176},{"period":"6month","weight":-0.1443},{"period":"1year","weight":-0.439},{"period":"ytd","weight":-0.3659}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.222509},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.068086},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.096837},{"month":4,"riseRate":0.555556,"avgChangeRate":-0.02827},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.131932},{"month":6,"riseRate":0.888889,"avgChangeRate":0.268748},{"month":7,"riseRate":0.666667,"avgChangeRate":0.046322},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.134581},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.094065},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.087088},{"month":11,"riseRate":0.555556,"avgChangeRate":0.039534},{"month":12,"riseRate":0.4,"avgChangeRate":0.002651}],"exchange":"NASDAQ","name":"Xenetic Biosciences Inc","nameEN":"Xenetic Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenetic Biosciences Inc(XBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenetic Biosciences Inc(XBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenetic Biosciences Inc,XBIO,Xenetic Biosciences Inc股票,Xenetic Biosciences Inc股票老虎,Xenetic Biosciences Inc股票老虎国际,Xenetic Biosciences Inc行情,Xenetic Biosciences Inc股票行情,Xenetic Biosciences Inc股价,Xenetic Biosciences Inc股市,Xenetic Biosciences Inc股票价格,Xenetic Biosciences Inc股票交易,Xenetic Biosciences Inc股票购买,Xenetic Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenetic Biosciences Inc(XBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenetic Biosciences Inc(XBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction